Divi’s Laboratories rallied 8% to Rs 1,090 on the BSE in early morning deal after the pharmaceutical company said that the US health regulator has completed evaluation of company’s corrective actions in response to FDA’s warning letter dated April 13.
“Further to our letter dated 2nd November, 2017, Divi's Laboratories has been informed by the U.S. Food and Drug Administration (US-FDA) that the Agency has completed evaluation of the Company's corrective actions in response to FDA's Warning Letter: 320-17-34 dated April 13, 2017,” the company said in a regulatory filing.
We also note from the update on FDA's
“Further to our letter dated 2nd November, 2017, Divi's Laboratories has been informed by the U.S. Food and Drug Administration (US-FDA) that the Agency has completed evaluation of the Company's corrective actions in response to FDA's Warning Letter: 320-17-34 dated April 13, 2017,” the company said in a regulatory filing.
We also note from the update on FDA's